← Back to Search

E-Selectin Antagonist

Uproleselan for COVID-19

Phase 1 & 2
Waitlist Available
Research Sponsored by Lena Napolitano, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during hospitalization; hospital stay ranged from 2 to 10 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing uproleselan, a drug that may help people with severe COVID-19 pneumonia recover faster and avoid worsening lung problems. It works by blocking a protein that causes inflammation and lung damage.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during hospitalization; hospital stay ranged from 2 to 10 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and during hospitalization; hospital stay ranged from 2 to 10 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety of Uproleselan - as Measured by Serious Adverse Events
Safety of Uproleselan- as Measured by Frequency of Serious Adverse Events
Secondary study objectives
Actual Duration of Hospitalization
Actual Duration of ICU Care
All-cause Mortality
+9 more

Side effects data

From 2022 Phase 2 trial • 51 Patients • NCT04682405
100%
Neutrophil count decreased
100%
Platelet count decreased
100%
Diarrhea
100%
White blood cell decreased
100%
Hypocalcemia
96%
Nausea
96%
Anemia
92%
Lymphocyte count decreased
88%
Fatigue
88%
Hypoalbuminemia
81%
Abdominal Pain
81%
INR increased
81%
Hypophosphatemia
69%
Hypokalemia
65%
Vomiting
50%
Esophageal Pain
50%
Mucositis oral
38%
Esophagitis
35%
Constipation
35%
Enterocolitis
35%
Fever
35%
Malaise
31%
Hyponatremia
31%
Hypotension
27%
Thrush
23%
Gastritis
23%
Dizziness
19%
Hemorrhoids
19%
Back Pain
15%
Edema Limbs
15%
Anorexia
15%
Proctitis
12%
Skin Infection
12%
Activated partial thromboplastin time prolonged
12%
Gastroesophageal Reflux Disease
12%
Eye Disorders - other
12%
Infections and Infestations - other
12%
Enterocolitis Infectious
12%
Alanine aminotransferase increased
12%
Blood bilirubin increased
12%
Dehydration
12%
Hyperglycemia
12%
Musculoskeletal and Connective Tissue Disorder - other
8%
Bruising
8%
Pain in Extremity
8%
Skin and Subcutaneous Tissue Disorders - other
8%
Flatulence
8%
Creatinine increased
8%
Aspartate aminotransferase increased
8%
Generalized Muscle Weakness
8%
Wheezing
8%
Periorbital Edema
8%
Febrile neutropenia
8%
Bloating
8%
Infusion Site Extravasation
8%
Hypernatremia
8%
Hyperphosphatemia
8%
Hypoglycemia
8%
Headache
8%
Peripheral Sensory Neuropathy
8%
Anxiety
8%
Dyspnea
4%
Neoplasms benign, malignant, and unspecified (incl cysts and polyps) - other
4%
Respiratory, Thoracic, and Mediastinal Disorders - other
4%
Sepsis
4%
Fall
4%
Hypertension
4%
Papulopustular Rash
4%
Dysphagia
4%
Facial Pain
4%
Urinary Tract Infection
4%
Alkaline phosphatase increased
4%
Sinusitis
4%
Vision Decreased
4%
Bacteremia
4%
Lung Infection
4%
Sinus Tachycardia
4%
Adrenal Insufficiency
4%
Dry Mouth
4%
Blurred Vision
4%
Extraocular Muscle Paresis
4%
Localized Edema
4%
Chills
4%
Toothache
4%
Generalized Edema
4%
Non-cardiac Chest Pain
4%
Otitis Externa
4%
Hyperkalemia
4%
Muscle Cramp
4%
Nervous System Disorders - other
4%
Encephalopathy
4%
Lethargy
4%
Psychiatric Disorders - other
4%
Testicular Pain
4%
Confusion
4%
Delirium
4%
Hallucinations
4%
Insomnia
4%
Restlessness
4%
Dysuria
4%
Hematuria
4%
Allergic Rhinitis
4%
Cough
4%
Nasal Congestion
4%
Pulmonary Edema
100%
80%
60%
40%
20%
0%
Study treatment Arm
Uproleselan + Standard of Care Melphalan
Placebo + Standard of Care Melphalan

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: UproleselanExperimental Treatment1 Intervention
Uproleselan injection is a sterile solution for IV administration, supplied in single-dose vials at a concentration of 50 mg/mL.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Uproleselan
2018
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Lena Napolitano, MDLead Sponsor
GlycoMimetics IncorporatedIndustry Sponsor
22 Previous Clinical Trials
1,470 Total Patients Enrolled
~2 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top